Of all the types of breast cancer, triple negative breast cancer is the most aggressive and lacks specific therapies. TNBC also is more likely to metastasize, or travel through the blood stream to spread to other organs, which causes most of breast cancer-related deaths each year.
Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.
